| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Primarily in vitro antimicrobial, wound healing, and immunomodulatory studies, plus mouse/rat models. Some topical human studies for chronic wounds exist but injectable/systemic LL-37 has no published human RCT. |
2 / 25 |
| Sample Size | No human systemic intervention participants. Very limited topical human studies with small n. |
0 / 20 |
| Replication | In vitro antimicrobial and immunomodulatory findings very well replicated across global labs. One of the most studied human antimicrobial peptides in preclinical science. |
15 / 20 |
| Journal Impact Factor | Published in PNAS (IF ~11), Journal of Immunology (IF ~5), Journal of Biological Chemistry (IF ~5), Antimicrobial Agents and Chemotherapy (IF ~5). Strong journal placement for preclinical work. |
8 / 15 |
| Funding Independence | NIH, Swedish Research Council, and academic funded. Independent academic research with no major commercial conflicts. |
7 / 10 |
| Population Diversity | Animal/in vitro. Not applicable. |
5 / 5 |
| Researcher h-Index | Birgitta Agerberth (Karolinska) and Robert Hancock (UBC) — both h-Index 60+. Among the most prominent antimicrobial peptide researchers globally. Capped at 5. |
4 / 5 |